Navigation Links
Signal Genetics and Pronto Diagnostics Announce Distribution Agreement
Date:4/4/2011

NEW YORK and TEL AVIV, Israel, April 4, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC, and Pronto Diagnostics Ltd, both of which are privately held predictive genetic testing companies focused on oncology, announced that they have entered into a Distribution Agreement whereby Pronto will be the exclusive representative and distributor for Signal's Myeloma Prognostic Risk Signature (MyPRS) test in Israel.  

According to Joe Hernandez, CEO of Signal Genetics, "The Agreement with Pronto Diagnostics represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology." Signal's MyPRS test is performed at the company's CLIA lab located in Little Rock, Arkansas and has been adopted by several highly reputable academic cancer centers throughout the U.S.

Dr. Nir Navot, Chairman and CTO of Pronto Diagnostics affirmed: "Our agreement with Signal Genetics allows us to provide a valuable prognostic tool to Israeli hematologists who treat Myeloma patients, in line with our commitment to increasing personalization of treatment for cancer patients".

About Signal Genetics

Signal Genetics, the parent company of Myeloma Health, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predictive outcome of disease stage, odds of relapse, and the optimal treatment regimen based on their specific genetic expression profile. Additional information is available at www.signalgenetics.com.

About Pronto Diagnostics

Pronto Diagnostics is a privately held company based in Tel Aviv that provides services for molecular diagnosis of disease with a focus on oncology, including the development and distribution of genetic testing kits.  Pronto has similar distribution relationships with several molecular diagnostic companies including Ipsogen, Pathwork Diagnostics, and Epigenomics. Additional information is available at www.prontodiagnostics.com.


'/>"/>
SOURCE Signal Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test
2. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
3. Signal Genetics Announces Establishment of Scientific Advisory Board
4. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
5. TRINAMIC Teams with Actel's SmartFusion™ Intelligent Mixed Signal FPGAs for Motion Control
6. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
7. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
8. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
9. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
10. Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection
11. Revealing the regulating mechanism behind signal transduction in the brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):